A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.

13 outlets ·Health & Medicine

How each outlet headlined it

STAT News
A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.
The Wall Street Journal right
Result in high-risk patients validates decades of research into mRNA-based therapeutic cancer vaccines. on.wsj.com/4zwRduC
CNBC left
Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial
Reuters
Merck, Moderna say melanoma vaccine meets goals in large trial reut.rs/4zqdji1
Financial Times center
Company’s melanoma cancer vaccine being developed with Merck
MarketWatch
The vaccine candidate pairs an mRNA therapy with the cancer drug Keytruda.
CNN left
Moderna’s mRNA vaccine combined with Merck’s immunotherapy Keytruda succeeded in a late-stage trial for skin cancer, the companies said, sending shares of the vaccine maker up 60% in premarket trading. https://cnn.it/4qqzOQ0
STAT
The personalized mRNA cancer vaccine, added to Merck's Keytruda, slowed the return of melanoma and its spread to other parts of the body in the study. www.statnews.com/2026/08/19/m...
Investing.com Stocks
mRNA cancer vaccine trial win ripples across biotech and oncology stocks
Bloomberg center
A personalized vaccine developed by Moderna and Merck reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology. Madison Muller explains (Source: Bloomberg)
The New York Times left
An experimental mRNA vaccine allowed people with high-risk melanoma to live longer, cancer-free, in a large, closely watched trial, the pharmaceutical companies Moderna and Merck announced Wednesday.
WSJ Markets
Plus, Moderna and Merck surge on mRNA cancer vaccine results.
Al Jazeera center
Moderna's mRNA vaccine Intismeran shows promise, reducing melanoma recurrence and spread in late-stage trials.